Results Of Phase 1b Clinical Trial Comparing Trevena, Inc. (TRVN)’s TRV130 To Morphine Published In The Journal Pain
6/24/2014 10:19:54 AM
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain. The manuscript, entitled "Biased agonism of the mu opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind placebo-controlled crossover study in healthy volunteers,” can be viewed online at the Pain website, http://www.painjournalonline.com/.
Help employers find you! Check out all the jobs and post your resume.
comments powered by